IGC Pharma 11/12/2024 Earnings Report $0.30 -0.03 (-8.92%) As of 02/21/2025 03:59 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Earnings HistoryForecast IGC Pharma EPS ResultsActual EPS-$0.02Consensus EPS -$0.03Beat/MissBeat by +$0.01One Year Ago EPSN/AIGC Pharma Revenue ResultsActual Revenue$0.41 millionExpected Revenue$0.29 millionBeat/MissBeat by +$120.00 thousandYoY Revenue GrowthN/AIGC Pharma Announcement DetailsQuarterDate11/12/2024TimeAfter Market ClosesConference Call ResourcesIGC Earnings History IGC Pharma Earnings HeadlinesIGC Pharma reports Q3 EPS (2c) vs. (9c) last yearFebruary 20 at 1:00 PM | markets.businessinsider.comIGC Pharma expands Holiby line with ‘Longevity’, ‘Renew’February 20 at 1:00 PM | markets.businessinsider.com$5,000 DOGE check?Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.February 22, 2025 | Altimetry (Ad)IGC Pharma, Inc.: IGC Pharma Reports Third Quarter Fiscal 2025 ResultsFebruary 18, 2025 | finanznachrichten.deIGC Pharma, Inc.: IGC Pharma Expands Into $75 Billion Wellness Market with the Launch of HolibyFebruary 11, 2025 | finanznachrichten.deIGC Pharma Appoints Former Virginia Governor Terry McAuliffe as Strategic AdvisorJanuary 21, 2025 | markets.businessinsider.comSee More IGC Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IGC Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IGC Pharma and other key companies, straight to your email. Email Address About IGC PharmaIGC Pharma (NYSEMKT:IGC), a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.View IGC Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles The Trade Desk Crashes on Earnings, But Growth Catalysts PersistHims & Hers Earnings Could Be a Game Changer—What to Do NowAnalysts See Buying Opportunity in NVIDIA Before EarningsAirbnb's Earnings: Sky High Results, Grounded Guidance?Is Coinbase Stock a Buy After Earnings?CVS Health: Earnings Beat Ignites Stock RallyQualcomm’s Post-Earnings Dip: A Prime Buying Opportunity? Upcoming Earnings Workday (2/24/2025)Intuit (2/25/2025)American Tower (2/25/2025)Bank of Montreal (2/25/2025)Bank of Nova Scotia (2/25/2025)Public Storage (2/25/2025)NVIDIA (2/26/2025)Synopsys (2/26/2025)Salesforce (2/26/2025)Lowe's Companies (2/26/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
